share_log

君聖泰醫藥-B：截至二零二四年五月三十一日止月份之股份發行人的證券變動月報表

HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Hong Kong Stock Exchange ·  Jun 3 11:36
Summary by Futu AI
君圣泰医药-B（HIGHTIDE-B）於2024年6月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本結存維持在1,000,000,000美元，每股面值0.0001美元，總額100,000美元，本月內無增減變動。此外，報告中確認了公司在本月內發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的所有要求。報告由執行董事兼行政總裁劉利平博士呈交。
君圣泰医药-B（HIGHTIDE-B）於2024年6月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本結存維持在1,000,000,000美元，每股面值0.0001美元，總額100,000美元，本月內無增減變動。此外，報告中確認了公司在本月內發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的所有要求。報告由執行董事兼行政總裁劉利平博士呈交。
JUN SHENG TAI PHARMACEUTICAL-B (HIGHTIDE-B) FILED ITS LATEST SECURITIES MONTH CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON JUNE 3, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF MAY 31, 2024. The report showed that the company's regulated/registered capital deposit remained at $1,000,000,000 with a face value of $0.0001 per share for a total of $100,000, with no increase or decrease during the month. In addition, the report confirms that the securities issued by the company during this month have been formally authorized by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. The report was presented by Dr. Liu Liping, Executive Director and Chief Executive Officer.
JUN SHENG TAI PHARMACEUTICAL-B (HIGHTIDE-B) FILED ITS LATEST SECURITIES MONTH CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON JUNE 3, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF MAY 31, 2024. The report showed that the company's regulated/registered capital deposit remained at $1,000,000,000 with a face value of $0.0001 per share for a total of $100,000, with no increase or decrease during the month. In addition, the report confirms that the securities issued by the company during this month have been formally authorized by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. The report was presented by Dr. Liu Liping, Executive Director and Chief Executive Officer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.